MDS/AML/AA in higher-risk and lower-risk patients in the intent-to-treat population and HRD-positive subgroup in the safety analysis set
| Higher risk | Lower risk | |||
| Olaparib + bevacizumab | Placebo + bevacizumab | Olaparib + bevacizumab | Placebo + bevacizumab | |
| Intent-to-treat population | n=398 | n=194 | n=137 | n=73 |
| Patients with MDS/AML/AA, n (%) | 7 (1.8) | 4 (2.1) | 2 (1.5) | 2 (2.7) |
| HRD-positive subgroup | n=177 | n=88 | n=78 | n=43 |
| Patients with MDS/AML/AA, n (%) | 4 (2.3) | 2 (2.3) | 2 (2.6) | 2 (4.7) |
HRD-positive defined as a tumor BRCAm and/or GIS ≥42 (MyChoice HRD Plus).
AA, aplastic anemia; AML, acute myeloid leukemia; BRCAm, BRCA1 and/or BRCA2 mutation; GIS, genomic instability score; HRD, homologous recombination deficiency; ITT, intent-to-treat; MDS, myelodysplastic syndrome.